HOME >> MEDICINE >> NEWS
Pioglitazone shown to reverse thickening of carotid artery wall

Mainz, Germany, November 9, 2004 Clinical study results presented today in New Orleans, Louisiana, during the American Heart Association's Scientific Sessions 2004 proceedings, have shown that the drug pioglitazone (ACTOS, Takeda) significantly reduced the thickness of the carotid (neck) artery in patients with type 2 diabetes. By contrast, no change in carotid thickness was seen in a group of patients who received glimepiride, an older drug for type 2 diabetes.

"These results are provocative, because both drugs showed similar effects on lowering blood glucose, the traditional principal target for type 2 diabetes therapy," noted principal investigator Thomas Forst, Professor for Internal Medicine, Institute for Clinical Research and Development in Mainz, Germany.

"The thickness of the carotid artery is an indicator of atherosclerotic disease, which may both reduce arterial blood flow and set the stage for unstable blood clots in the arteries to dislodge and potentially cause a heart attack or stroke. The reduction in thickness by pioglitazone, a member of a new class of type 2 diabetes drugs called thiazolidinediones (TZDs) suggests that this medication may have benefits beyond improving metabolic control in patients with diabetes mellitus type 2," continued Forst. "This substantial regression of carotid intima media thickness over just 12 or 24 weeks may have important prognostic implications for patients with type 2 diabetes."

Study Design and Results

In the study, B-mode ultrasound was used to measure the intima media thickness (IMT) of the carotid artery before and 12 and 24 weeks after 173 patients received oral therapy with either pioglitazone (45 mg/day) or glimepiride (1-6 mg/day). Baseline carotid IMT was 0.949 0.149mm in the pioglitazone group and 0.924 0.150mm in the glimepiride group (p=n.s.). Carotid IMT was reduced only in the pioglitazone group after 12 weeks (-0.033 0.052mm) vs. -0.002 0.047mm
'"/>

Contact: Kate Sullivan
646-284-6514
Ketchum
9-Nov-2004


Page: 1 2

Related medicine news :

1. Pioglitazone HCI shown to lower blood pressure in hypertensive patients with type 2 diabetes
2. Cartilage repair techniques shown to restore patient mobility and reduce pain
3. Sprinklers shown effective in slowing dorm fires
4. Controversial drug shown to act on brain protein to cut alcohol use
5. HPV vaccine shown effective at reducing cancer-causing infections
6. HPV vaccine shown to substantially reduce cervical cancer
7. New research results: Heart jacket shown to be effective
8. Isolated soy protein shown to benefit type 2 diabetics, study indicates
9. Increased risk of cardiovascular disease shown in PCOS patients
10. Combination therapy w/ ACTOS (pioglitazone HCI) shown to improve components of diabetic dyslipidemia
11. Anti-eosinophil therapy shown to be effective in treating hypereosinophilic syndrome

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
Cached News: